Company profile: MannKind
1.1 - Company Overview
Company description
- Provider of inhaled and wearable therapeutic products and platforms for diabetes and pulmonary diseases, including Afrezza (inhaled insulin), Tyvaso DPI (treprostinil for PAH and PH-ILD), Clofazimine Inhalation Suspension (for NTM lung disease), Nintedanib DPI (for pulmonary fibrotic diseases), V-Go (wearable insulin delivery), and Technosphere Technology for dry powder inhalation formulations.
Products and services
- Afrezza: A pharmaceutical-grade inhaled insulin powder that manages blood sugar levels in patients with diabetes, delivering insulin through pulmonary administration with powder-based dosing
- Technosphere Technology: A modular platform that develops dry powder formulations for inhalation, compatible with a wide range of active pharmaceutical ingredients for broad formulation compatibility
- Tyvaso DPI: An inhalation-optimized dry powder formulation of treprostinil that treats pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease via pulmonary delivery
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MannKind
Elutia
HQ: United States
Website
- Description: Provider of customized tissue products, including CanGaroo, an acellular envelope for securing implantable electronic devices to promote healthy tissue integration and wound healing; SimpliDerm, a human acellular dermal matrix for soft tissue reconstruction with rapid integration and revascularization and a low inflammatory response; and CanGarooRM, a next-generation drug-eluting biomatrix for securing cardiac devices or neurostimulators.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elutia company profile →
Sedana Medical
HQ: Sweden
Website
- Description: Provider of anaesthetic delivery systems and agents, including the AnaConDa (Anaesthetic Conserving Device) for delivering anaesthetic agents during medical procedures; Sedaconda (isoflurane) for sedation with AnaConDa; Sedasource for continuous anaesthetic agent supply; and FlurAbsorb to absorb and manage anaesthetic gases in medical settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sedana Medical company profile →
Alexza
HQ: United States
Website
- Description: Provider of inhaled therapeutics for acute and intermittent conditions, featuring commercial ADASUVE (loxapine) for acute agitation in adults with schizophrenia or bipolar disorder, and developing Staccato inhalation candidates: alprazolam for epileptic seizures, apomorphine for OFF episodes in Parkinson’s disease, and granisetron for cyclic vomiting syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alexza company profile →
MedinCell
HQ: France
Website
- Description: Provider of injectable slow-release drug expertise.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MedinCell company profile →
Lyra Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics for ear, nose, and throat diseases, including LYR-210 and LYR-220, bioabsorbable nasal mesh implants that deliver up to six months of continuous mometasone furoate for chronic rhinosinusitis, and the XTreo platform, a proprietary technology for direct, consistent, sustained drug delivery to affected tissues with a single administration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lyra Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MannKind
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MannKind
2.2 - Growth funds investing in similar companies to MannKind
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MannKind
4.2 - Public trading comparable groups for MannKind
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →